LivaNova PLC
LIVN
Kedudukan dalam Saham
#3785
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Harga Saham
$80.35
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$4.41B
Perubahan (1 hari)
2.83%
Perubahan (1 tahun)
46.87%
Negara
GB
Perdagangan LivaNova PLC (LIVN)
Kategori
Healthcare
Nisbah P/E bagi LivaNova PLC (LIVN)
Nisbah P/E pada October 2026 TTM: 22.05
Menurut laporan kewangan dan harga saham terkini LivaNova PLC, nisbah P/E semasa (TTM) ialah 22.05. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak 158.94.
Sejarah nisbah P/E bagi LivaNova PLC dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 22.05 | -44.48% |
| 2024 | 39.72 | -75.01% |
| 2023 | 158.94 | -561.33% |
| 2022 | -34.45 | 5.61% |
| 2021 | -32.62 | 248.10% |
| 2020 | -9.37 | -60.04% |
| 2019 | -23.45 | 0.14% |
| 2018 | -23.42 | -84.74% |
| 2017 | -153.47 | 338.64% |
| 2016 | -34.99 | -229.17% |
| 2015 | 27.09 | -34.95% |
| 2013 | 41.64 | -22.80% |
| 2012 | 53.94 | 28.48% |
| 2011 | 41.98 | 70.00% |
| 2010 | 24.69 | -64.57% |
| 2009 | 69.70 | -138.87% |
| 2008 | -179.31 | 414.34% |
| 2007 | -34.86 | 18.18% |
| 2006 | -29.50 | -78.56% |
| 2005 | -137.57 | -157.59% |
| 2004 | 238.87 | -19.62% |
| 2003 | 297.18 | -612.60% |
| 2002 | -57.98 | 0.00% |
| 2001 | 0.00 | -100.00% |
| 2000 | -413.29 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 33.11 | 50.14% |
US
|
|
| 21.39 | -3.01% |
IE
|
|
| 28.94 | 31.25% |
US
|
|
| 17.34 | -21.37% |
US
|
|
| - | - |
DE
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.